trending Market Intelligence /marketintelligence/en/news-insights/trending/gntbzcy0xkuqydxihdjcsq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Imugene closes A$8.1M rights issue

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Imugene closes A$8.1M rights issue

Australia's Imugene Ltd. closed a previously announced fully underwritten 1-for-9.5 rights issue.

Shareholders subscribed for 139,713,059 shares at 2.7 Australian cents each. The cancer drug developer raised about A$3.8 million.

The resulting shortfall of 160,803,118 shares will be allocated to institutional investors.

The company expects to complete the issue of shares and attaching options under the rights issue July 11.

Imugene develops immunotherapies for gastric and breast cancer.